Mortality at maximal · alcohol‐related disorders (others)
It is very uncertain whether colchicine changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · people with primary biliary cholangitis
1 finding from 1 review
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether colchicine changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Pain ‐ not reported · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
Low‐dose colchicine may leads to higher participant global assessment of treatment success: proportion with… compared with placebo (low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · acute gout
1 finding from 1 review
Global assessment of treatment success · acute gout
Low‐dose colchicine showed no clear difference in participant global assessment of treatment success: Completely… compared with NSAIDs (low certainty).
1 finding from 1 review
Reduction of inflammation ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants reporting an adverse event · acute gout
Low‐dose colchicine showed no clear difference in total number of participants reporting adverse events compared with NSAIDs (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Reduction of inflammation ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review